前沿生物-U
(688221)
| 流通市值：70.80亿 | | | 总市值：70.80亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 103,373,939.22 | 58,639,825.88 | 28,328,182.53 | 129,472,935.98 |
| 营业收入 | 103,373,939.22 | 58,639,825.88 | 28,328,182.53 | 129,472,935.98 |
| 二、营业总成本 | 262,354,974.69 | 159,170,063.11 | 74,909,155.77 | 405,686,029.6 |
| 营业成本 | 67,356,219.4 | 40,468,036.68 | 19,130,499.87 | 85,546,537.91 |
| 税金及附加 | 2,385,541.78 | 1,564,162.01 | 775,150.96 | 4,597,169.4 |
| 销售费用 | 65,858,144.17 | 37,676,114.99 | 21,243,275.06 | 86,344,001.84 |
| 管理费用 | 43,902,955.74 | 32,416,374.22 | 17,144,817.33 | 84,816,363.24 |
| 研发费用 | 83,870,664.18 | 47,936,469.2 | 16,803,233.38 | 137,205,648.06 |
| 财务费用 | -1,018,550.58 | -891,093.99 | -187,820.83 | 7,176,309.15 |
| 其中:利息费用 | 6,817,412.49 | 4,670,816.41 | 2,363,345.93 | 10,271,685.7 |
| 其中:利息收入 | 8,420,692.35 | 5,901,767.72 | 2,804,501.34 | 4,120,130.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -725,728.39 | -297,011.44 | -206,446.41 | 83,505.51 |
| 加:投资收益 | -5,778,666.97 | -1,861,944.89 | 461,621.71 | 84,091,885.06 |
| 资产处置收益 | -22,430.99 | 15,353.93 | 15,353.93 | 18,798.64 |
| 资产减值损失(新) | -1,576,076.24 | -89,923.13 | -152,429.13 | -46,727,551.35 |
| 信用减值损失(新) | -2,802,286.87 | -1,443,018.17 | -897,500.57 | 253,226.64 |
| 其他收益 | 10,410,236.6 | 7,058,376.99 | 3,224,253.28 | 37,399,668.2 |
| 四、营业利润 | -159,475,988.33 | -97,148,403.94 | -44,136,120.43 | -201,093,560.92 |
| 加:营业外收入 | 23,101.96 | 21,040.01 | 16,187.67 | 22,845.66 |
| 减:营业外支出 | 355,639.7 | 225,246.75 | 1,584.65 | 311,895.13 |
| 五、利润总额 | -159,808,526.07 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 |
| 六、净利润 | -159,808,526.07 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -159,808,526.07 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -159,808,526.07 | -97,352,610.68 | -44,121,517.41 | -201,382,610.39 |
| 扣除非经常损益后的净利润 | -185,228,750.55 | -114,735,072.42 | -53,145,687.62 | -327,311,199.95 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.43 | -0.26 | -0.12 | -0.54 |
| (二)稀释每股收益 | -0.43 | -0.26 | -0.12 | -0.54 |
| 八、其他综合收益 | 17,530.76 | 16,756.4 | 21,559.46 | 11,919.84 |
| 归属于母公司股东的其他综合收益 | 17,530.76 | 16,756.4 | 21,559.46 | 11,919.84 |
| 九、综合收益总额 | -159,790,995.31 | -97,335,854.28 | -44,099,957.95 | -201,370,690.55 |
| 归属于母公司股东的综合收益总额 | -159,790,995.31 | -97,335,854.28 | -44,099,957.95 | -201,370,690.55 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |